Dane Leone
Stock Analyst at Raymond James
(1.19)
# 3,771
Out of 5,246 analysts
65
Total ratings
32%
Success rate
-5.16%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $23 → $26 | $13.53 | +92.17% | 4 | May 19, 2026 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $84 → $56 | $8.28 | +576.33% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $6.35 | +608.66% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $151.56 | -80.21% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $638.88 | +48.70% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $3.03 | +329.04% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $69.12 | -33.45% | 2 | Jul 18, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $2.07 | +286.47% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $8.23 | +70.11% | 5 | Nov 8, 2022 | |
| XNCR Xencor | Upgrades: Strong Buy | $58 | $11.31 | +412.82% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $15.37 | +355.43% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.00 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $76.94 | -18.12% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $59.46 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.5012 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $62.26 | +4.40% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $339.30 | -24.85% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $3.80 | +742.11% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $234.34 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
May 19, 2026
Maintains: Strong Buy
Price Target: $23 → $26
Current: $13.53
Upside: +92.17%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $84 → $56
Current: $8.28
Upside: +576.33%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $6.35
Upside: +608.66%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $151.56
Upside: -80.21%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $638.88
Upside: +48.70%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $3.03
Upside: +329.04%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $69.12
Upside: -33.45%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $2.07
Upside: +286.47%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $8.23
Upside: +70.11%
Xencor
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $11.31
Upside: +412.82%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $15.37
Upside: +355.43%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.00
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $76.94
Upside: -18.12%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $59.46
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.5012
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $62.26
Upside: +4.40%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $339.30
Upside: -24.85%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $3.80
Upside: +742.11%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $234.34
Upside: -